Aethlon MedicalAEMD -6.07%23 Forward Dividend Yield % is 0.00% as of Jul. 03, 2026. GuruFocus rates AEMD with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 315 Medical Devices & Instruments companies, Aethlon Medical ranks worse than 317460% on this metric.
As of today (2026-07-03), the Forward Annual Dividend Yield of Aethlon Medical is 0.00%.
As of today (2026-07-03), the Trailing Annual Dividend Yield of Aethlon Medical is 0.00%.
AEMD's Forward Dividend Yield % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.03 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Aethlon Medical (NAS:AEMD) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Aethlon Medical Forward Dividend Yield % Related Terms
AEMD vs VYCO, RBOT, ESMC: Forward Dividend Yield % Comparison
For the Medical Devices subindustry, Aethlon Medical's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aethlon Medical Forward Dividend Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aethlon Medical's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Aethlon Medical's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Aethlon Medical (AEMD) has a Forward Dividend Yield % of 0.00% as of Jul. 03, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Aethlon Medical and its competitors. According to the industry distribution chart, Aethlon Medical ranks #999999 out of 315 companies in the Medical Devices & Instruments industry.
Is Aethlon Medical's Forward Dividend Yield % too high?
Aethlon Medical's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Aethlon Medical ranks #999999 out of 315 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Aethlon Medical has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Aethlon Medical's Forward Dividend Yield % compare to VYCO and RBOT?
According to the Medical Devices & Instruments industry distribution chart, Aethlon Medical ranks #999999 out of 315 companies for Forward Dividend Yield %. This places Aethlon Medical in the lower half of its industry. The industry median Forward Dividend Yield % is 2.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Devices & Instruments company?
The median Forward Dividend Yield % among Medical Devices & Instruments companies is 2.03, based on 315 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Aethlon Medical and its competitors. For the Medical Devices & Instruments industry, the median Forward Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aethlon Medical's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aethlon Medical stock overvalued right now?
Aethlon Medical (AEMD) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Aethlon Medical's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Aethlon Medical (AEMD), the current Forward Dividend Yield % is 0.00% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
23GF Score
Get the complete analysis for AEMD
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AEMD has been successfully added to your 